Clinical trials: Induction Chemotherapy
Esophageal Squamous Cell Carcinoma
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
This Phase I study is to determine the maximum tolerated fraction dose (MTD) for split-course hypo-CCRT following induction chemo-immunotherapy in LA-ESCC patients, to clarify the dosimetric advantage of split-course hypo-CCRT…
- Trial name
- NCT06020885
- Testing
- Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Chronic Pain, Opioid Use Disorder
Cannabidiol in Opioid Use Disorder and Chronic Pain
This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use…
- Trial name
- NCT04587791
- Testing
- 400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Breast Cancer
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
- Trial name
- DAPA-MYOCANCER (NCT06711185)
- Testing
- Dapagliflozin 10 mg
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Campinas, Brazil
Leukemia, Myeloid
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine.
- Trial name
- NCT04748848
- Testing
- CC-90011, Venetoclax, Azacitidine
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Esophageal Carcinoma
Induction Chemotherapy for Locally Advanced Esophageal Cancer
Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced…
- Trial name
- NCT03110926
- Testing
- mFOLFOX6, Chemoradiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Rochester
Cardiotoxicity, Atherosclerosis
Atherosclerosis in Chemotherapy-related Cardiotoxicity
Cardiological complications of oncological treatment, including the most serious of them cardiotoxicity and heart failure, constitute a significant and still unsolved clinical problem.
- Trial name
- ANTEC (NCT05118178)
- Testing
- echocardiography, computed tomography
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Nasopharyngeal Carcinoma
Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Researchers conduct the clinical trial (gemcitabine combined with cisplatin induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine for locally advanced nasopharyngeal carcinoma) to evaluate the safety…
- Trial name
- NCT04522050
- Testing
- Gemcitabine combined with cisplatin induction chemotherapy, concurrent chemoradiotherapy with gemcitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chemotherapy-induced Nausea and Vomiting, Pediatric Cancer
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients.
- Trial name
- NCT06120764
- Testing
- guided imagery
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Baskent University
Breast Neoplasms, Fatigue
Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients
Breast cancer is the most frequent cancer in women and is associated with profound restrictions of health-related quality of life and psychosocial health.
- Trial name
- IFaB (NCT01686737)
- Testing
- Iyengar Yoga, Walking
- Where
- 2 sites in Germany
- Sponsor
- Universität Duisburg-Essen
Breast Cancer
Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Melatonin is an attractive candidate with anticancer activities previously reported in various preclinical and clinical studies.
- Trial name
- NCT07067307
- Testing
- melatonin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Nasopharyngeal Carcinoma, Pathologic Complete Response
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle…
- Conditions
- Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
- Trial name
- NCT06182657
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Hematologic Neoplasms
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
This study will investigate the safety and effectiveness of a modified stem cell transplant procedure for treating cancers of the blood and immune system.
- Trial name
- NCT00051311
- Testing
- Stem cell transplantation, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Hypopharyngeal Cancer, Immunotherapy
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
The study is a single center phase II trial. The purpose is to investigate both the efficacy and safety of chemotherapy combined with anti-PD-1 antibody Followed by chemoradiotherapy in locoregionally advanced hypopharyngeal…
- Conditions
- Hypopharyngeal Cancer, Immunotherapy, Induction Chemotherapy
- Trial name
- NCT04539600
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
The purpose of this trial is to compare two different treatments for fit patients with head and neck cancer: All patients are given induction-chemotherapy (docetaxel, cisplatin, 5-FU).
- Trial name
- Condor (NCT00774319)
- Testing
- conventional radiotherapy with 'high' dose cisplatin, accelerated radiotherapy with 'low' dose cisplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Chemotherapy-induced Nausea and Vomiting
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in…
- Trial name
- NCT03601871
- Testing
- Thalidomide, Dexamethasone, 5-HT3 antagonists
- Where
- 29 sites in China
- Volunteers
- 880 people
- Sponsor
- Yunpeng Liu
Psilocybin, Neuropathy
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study…
- Trial name
- NCT07227909
- Testing
- Psilocybin (drug), Standard of Care (SOC)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC
Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy
Immunotherapy is a crucial first-line treatment for advanced non-small cell lung cancer (NSCLC) without gene mutations. However, chemotherapy-induced pneumonitis (CIP) is a common adverse effect of immunotherapy, with severe…
- Trial name
- NCT07243899
- Testing
- This study is an observational study; the intervention is not applicable.
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Chronic Myeloid Leukemia
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
This is an extension of our ongoing clinical trial using ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy for haematological malignancies.
- Trial name
- NCT00815321
- Testing
- Autologous CIK cell infusion
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Singapore General Hospital
Anemia
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.
- Trial name
- NCT02767765
- Testing
- r-HuEPO
- Where
- 7 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.